The EMA pulled the license of Taiwan’s Savior Lifetec Corp. after a plant inspection in March turned up a variety of problems.

China's WuXi Biologics and Sinobioway will build biologics facilities; Takeda expects Velcade freefall and looks to offload R&D assets to cut costs.

The combined value of those assets on the for-sale list, which include Novartis' U.S. generics dermatology business, could reach $2 billion.

Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.

A yearlong struggle for control of Chinese vaccine maker Sinovac Biotech has forced the company to suspend manufacturing of its hepatitis A vaccine.

Shire and Takeda have agreed on a deal. Now, it's up to the Japanese drugmaker to make the $62 billion deal pay off—and job cuts will be part of that.

AstraZeneca is back at it again with its asset sales. The company offloaded certain Seroquel rights to Luye Pharma for up to $538 million.

The solid-dose API operation of WuXi had its first visit by FDA inspectors at a new plant in Changzhou, China, and the company says it aced it.

Merck's Gardasil rollout in China helped the vaccine franchise grow sales 24% in the first quarter.